Leadership Team
The Breakthrough Leadership Team has dedicated their careers to the investment, construction and operations of best-in-class life science real estate.
Dan Belldegrun
Chief Executive Officer and Co-Founder
Daniel D’Orazi
EVP and Chief Investment Officer
Susie Harborth
Chief Business Officer
Lesley Chao
Chief Financial Officer
Christian Heimple
SVP, Design & Construction
Sabine Heller
SVP and Chief Experience Officer
Aaron Kazam
SVP, Acquisitions
Thomas Renn
SVP, Acquisitions & Development, Europe
Kinsey Sale
SVP, Asset Management
Jennifer Warne
SVP, Legal and Chief Compliance Officer
Peter Oden
VP, Portfolio Management
BOARD OF DIRECTORS
Breakthrough Properties is backed by a joint venture between Tishman Speyer and Bellco Capital.
Rob Speyer
Tishman Speyer
President and Chief Executive Officer
President and Chief Executive Officer
Arie Belldegrun, M.D.
Bellco Capital
Chairman
Chairman
Rebecka Belldegrun, M.D.
Bellco Capital
Founder and Chief Executive Officer
Founder and Chief Executive Officer
Jeffrey Mandel
Tishman Speyer
Senior Managing Director, Co-Head of US Acquisitions
Senior Managing Director, Co-Head of US Acquisitions
Joseph Doran
Tishman Speyer
Senior Managing Director, Chief Financial Officer
Senior Managing Director, Chief Financial Officer
Joshua Kazam
Two River Group
Co-Founder and Partner
Co-Founder and Partner
Michael Benner
Tishman Speyer
Senior Managing Director, General Counsel
Senior Managing Director, General Counsel
Josh Bradley
Bellco Capital
Chief Investment Officer
Chief Investment Officer
Scientific Advisory Board
Our world-renowned Scientific Advisory Board (“SAB”) of leading scientists, entrepreneurs, CEOs and venture capital investors bring their decades of experience to our unique platform for the benefit of our client-tenants.
Arie Belldegrun, M.D.
Executive Chairman and Co-Founder of Allogene, Chairman of Bellco Capital, Two River Group, UroGen Pharma and Kronos Bio
Franz Humer, M.D.
Chairman of Humer Foundation, Former Chairman and CEO of Roche Holding
Liz Barrett
CEO of UroGen Pharma, Former CEO of Oncology at Novartis
Owen N. Witte, M.D.
UCLA Professor of Microbiology, Immunology, and Molecular Genetics & President’s Chair of Development Immunology
David Chang, M.D., PhD
Co-Founder and CEO of Allogene Therapeutics, Former Chief Medical Officer of Kite Pharma
Helen Kim
Managing Director at Vida Ventures, Former Partner at Column Group and Executive Vice President of Business Development at Kite Pharma
Arjun Goyal, M.D., MBA
Co-Founder and Managing Director at Vida Ventures, Former Investment Professional at 5AM Ventures
Stefan Vitorovic
Co-Founder and Managing Director at Vida Ventures, Former Investment Professional at Third Rock
Ben Belldegrun
Managing Director and Founder of Pontifax AgTech, Former Portfolio Manager for Brevan Howard Asset Management
Amy Schulman
Managing Partner at Polaris Partners, Former general counsel at Pfizer and President, Pfizer Consumer Healthcare
Jakob Loven, PhD
Managing Partner at Nextech Invest; co-founder Relay Therapeutics (NASDAQ: RLAY) and Syros Pharmaceuticals (NASDAQ: SYRS)
